B. Braun Medical Inc. has acquired the Medisystems Streamline Bloodlines business. The acquired bloodline systems will include the Streamline Bloodline for the Dialog+ hemodialysis system, Streamline Bloodline for the Fresenius Medical Care hemodialysis system, and Streamline Bloodline Long for the Fresenius Medical Care hemodialysis system.
 
Sam Amory, vice president of B. Braun Medical’s Avitum Division, said, “We are pleased to add the Streamline bloodline to our dialysis product portfolio. Although we have been selling Streamline for many years, this acquisition will allow us to more broadly promote Streamline’s benefits as part of our transformative system of products, which includes the Dialog hemodialysis machine and the Diacap PRO dialyzer.”
 
The inclusion of Streamline Bloodlines is one more addition to the complete integrated line of dialysis products B. Braun’s Avitum division currently offers. 
 
B. Braun Medical Inc., a developer of infusion therapy and pain management, manufactures and markets medical products and services to the healthcare industry. Other key product areas include nutrition, pharmacy admixture and compounding, ostomy and wound care, and dialysis. The company is committed to eliminating preventable treatment errors and enhancing patient, clinician and environmental safety. B. Braun Medical is headquartered in Bethlehem, Pa., and is part of the B. Braun Group of Companies in the United States, which includes B. Braun Interventional Systems, Aesculap and CAPS.
 
Globally, the B. Braun Group of Companies employs more than 61,000 employees in 64 countries. Guided by its Sharing Expertise philosophy, B. Braun continuously exchanges knowledge with customers, partners and clinicians to address the critical issues of improving care and lowering costs.